PT  - JOURNAL ARTICLE
AU  - Vasilios Tzilas
AU  - Argyrios Tzouvelekis
AU  - Evangelos Bouros
AU  - Matthew Katsaras
AU  - Maria Ntassiou
AU  - Theodoros Karampitsakos
AU  - Demosthenes Bouros
TI  - Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis
AID  - 10.1183/13993003.congress-2019.PA4733
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA4733
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA4733.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA4733.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Introduction: Chronic Hypersensitivity Pneumonitis (c-HP) can exhibit an IPF-like course despite immunosuppressive treatment. In this group of patients there is a need for new therapeutic approaches.Aim: To investigate the effect of antifibrotics in the clinical course of c-HP.Patients and Methods: Retrospective analysis of patients with an initial diagnosis of IPF that were subsequently diagnosed as c-HP in the context of multidisciplinary discussion (Jan2012-Dec2016). HP diagnosis was based in the absence of alternative diagnoses when at least two of the following criteria were present: Recognition of an inciting antigen, compatible HRCT pattern (mainly presence of mosaic pattern), BAL lymphocytosis>20%.Results: We enrolled in the study 96 patients with HP. From this cohort we identified 18 patients, initially diagnosed as IPF (16 males, 88,9%, median age 70 years (95% CI for the median 63 to 73.6) that had received antifibrotics for at least 12 months (10 pirfenidone and 8 nintedanib). Mean (±SE) relative changes in %FVCpred and %DLcopred over one year was -4.19±3.29 and -5.72±5.32, respectively. A decline in FVC was observed in 11 patients (in 4 patients > 10%, and in 5 patients between 5-10%). An increase in relative %FVCpred was observed in 7 patients (mean ΔFVC ± SE = 8.69±3.75).Conclusions: Antifibrotics can stabilize FVC decline in patients with c-HP. Large randomized trials are needed.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4733.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).